Table 4.
CTCAE grade* | Baseline | 4–6 weeks | 3 months | ||||||
---|---|---|---|---|---|---|---|---|---|
0 (%) | 1 + 2 (%) | 3 + 4 (%) | 0 (%) | 1 + 2 (%) | 3 + 4 (%) | 0 (%) | 1 + 2 (%) | 3 + 4 (%) | |
ALP | 47 | 51 | 2 | 25 | 75 | 25 | 75 | ||
γGT | 15 | 47 | 38 | 5 | 41 | 54 | 3 | 31 | 66 |
AST | 75 | 23 | 2 | 64 | 36 | 55 | 45 | ||
ALT | 79 | 21 | 78 | 22 | 76 | 22 | 2 | ||
Bilirubin | 95 | 5 | 90 | 8 | 3 | 87 | 10 | 3 | |
Albumin | 73 | 27 | 64 | 36 | 55 | 45 | |||
LDH | 61 | 37 | 2 | 56 | 44 | 69 | 28 | 3 | |
Haemoglobin | 27 | 73 | 29 | 71 | 25 | 75 | |||
Leucocytes | 75 | 25 | 77 | 23 | 75 | 23 | 2 | ||
Lymphocytes | 45 | 32 | 23 | 18 | 54 | 26 | 25 | 33 | 42 |
Platelets | 82 | 17 | 2 | 69 | 29 | 2 | 70 | 28 | 3 |
INR | 100 | 100 | 100 |
CTCAE Common terminology criteria for adverse events version 4.03, ALP alkaline phosphatase, γGT γ-glutamyl transpeptidase, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate dehydrogenase and INR International Normalized Ratio